240 related articles for article (PubMed ID: 17709172)
1. Editorial comment on: decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
Finney Rutten LJ
Eur Urol; 2008 Jun; 53(6):1193. PubMed ID: 17709172
[No Abstract] [Full Text] [Related]
2. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
Rittmaster R
Eur Urol; 2008 Sep; 54(3):514-5. PubMed ID: 18585846
[No Abstract] [Full Text] [Related]
3. Biopsies for "normal" PSA? Certain relatively young, healthy men with PSA levels below 4 should consider having a biopsy.
Gerber GS
Health News; 2004 Jul; 10(7):4-5. PubMed ID: 15239153
[No Abstract] [Full Text] [Related]
4. Editorial comment on: Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
Stanislaus P; Seitz M
Eur Urol; 2009 Apr; 55(4):909-10. PubMed ID: 18485577
[No Abstract] [Full Text] [Related]
5. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
Hoffman RM; Couper MP; Zikmund-Fisher BJ; Levin CA; McNaughton-Collins M; Helitzer DL; VanHoewyk J; Barry MJ
Arch Intern Med; 2009 Sep; 169(17):1611-8. PubMed ID: 19786681
[TBL] [Abstract][Full Text] [Related]
6. "It's a maybe test": men's experiences of prostate specific antigen testing in primary care.
Evans R; Edwards AG; Elwyn G; Watson E; Grol R; Brett J; Austoker J
Br J Gen Pract; 2007 Apr; 57(537):303-10. PubMed ID: 17394734
[TBL] [Abstract][Full Text] [Related]
7. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
[TBL] [Abstract][Full Text] [Related]
8. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
Malavaud B
Eur Urol; 2008 Sep; 54(3):515-6. PubMed ID: 18585850
[No Abstract] [Full Text] [Related]
9. Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
Avery KN; Blazeby JM; Lane JA; Neal DE; Hamdy FC; Donovan JL
Eur Urol; 2008 Jun; 53(6):1186-93. PubMed ID: 17709169
[TBL] [Abstract][Full Text] [Related]
10. Editorial comment: factor that influence serum prostate-specific antigen levels in terms of maintaining quality within a PSA screening system.
Ito K
Eur Urol; 2007 Sep; 52(3):714. PubMed ID: 17849514
[No Abstract] [Full Text] [Related]
11. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels.
Dai B; Ye DW; Kong YY; Shen YJ; Wang BH
Asian J Androl; 2008 Mar; 10(2):325-31. PubMed ID: 18097514
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.
Autorino R; Perdonà S; Di Lorenzo G
Urology; 2010 Nov; 76(5):1076; author reply 1076-7. PubMed ID: 21056255
[No Abstract] [Full Text] [Related]
13. Editorial comment on: reassessing the diagnostic yield of saturation biopsy of the prostate.
Philip J
Eur Urol; 2008 May; 53(5):981-2. PubMed ID: 17997013
[No Abstract] [Full Text] [Related]
14. Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA values.
Chun FK; Briganti A
Eur Urol; 2008 Sep; 54(3):702. PubMed ID: 18403097
[No Abstract] [Full Text] [Related]
15. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
Schröder FH; Roobol MJ
Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
[TBL] [Abstract][Full Text] [Related]
16. Editorial comment on: reassessing the diagnostic yield of saturation biopsy of the prostate.
Patel A
Eur Urol; 2008 May; 53(5):982-3. PubMed ID: 17997023
[No Abstract] [Full Text] [Related]
17. Editorial comment.
Epstein JI
J Urol; 2010 Mar; 183(3):1001. PubMed ID: 20089268
[No Abstract] [Full Text] [Related]
18. Editorial comment.
Vollmer RT
J Urol; 2010 Mar; 183(3):1001-2. PubMed ID: 20089267
[No Abstract] [Full Text] [Related]
19. Re: Billis et al.: Does the type of prostatic atrophy influence the association of extent of atrophy in needle biopsies and serum prostate-specific antigen levels? (Urology 2009;74:1111-1115).
Papatsoris A; Albanis S; Deliveliotis C
Urology; 2010 May; 75(5):1239; author reply 1240. PubMed ID: 20451754
[No Abstract] [Full Text] [Related]
20. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
Shao Q; Song J; Zhou ZJ; Du LD
Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
